Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
AssigneeBoard of Regents, The University of Texas System
InventorsDihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
Life of this patent
Estimating the term…
Abstract
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Claims6
A method for administering a treatment regimen comprising an effective amount of a P13K inhibitor, said method comprising:
- (1) assaying a patient sample comprising at least one test cancer cell to measure the amount of PTEN protein having the amino acid sequence of SEQ ID NO:2 using at least one technique chosen from the group consisting of immunohistochemistry, immunoprecipitation, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, western blot, antibody array, and FACS analysis;
- (2) comparing the amount of PTEN protein measured in (1) to a reference amount of PTEN protein in reference cancer cells of a reference cohort of patients who are not candidates for said treatment regimen;
- and
- (3) administering said treatment regimen to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 50% of said reference amount of PTEN protein in (2).
A method for administering a first treatment regimen comprising an effective amount of a PI3K inhibitor, said method comprising:
- (1) assaying a patient sample comprising at least one test cancer cell to measure the amount of PTEN protein having the amino acid sequence of SEQ ID NO:2 using at least one technique chosen from the group consisting of immunohistochemistry, immunoprecipitation, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, western blot, antibody array, and FACS analysis;
- (2) comparing the amount of PTEN protein measured in (1) to a reference amount of PTEN protein in reference cancer cells of a reference cohort of patients who are not candidates for said first treatment regimen;
- and
- (3) (a) administering said first treatment regimen to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 50% of said reference amount of PTEN protein in (2);
- or
- (3) (b) administering a second treatment regimen comprising trastuzumab to a test patient for whom said at least one test cancer cell is measured in (1) to have an amount of PTEN protein that is greater than 50% of said reference amount of PTEN protein in (2).
Dependencies are inferred from the claim text.